Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voruciclib in Relapsed/Refractory B Cell Malignancies or AML
NCT03547115Phase 1Terminated
- Sponsor
- MEI Pharma
- Start
- May 2018
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of voruciclib in follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) and 4 more, sponsored by MEI Pharma. Primary endpoints: Safety and tolerability of voruciclib at 2 years and Safety and tolerability of voruciclib in combination with venetoclax at 2 years. Started May 2018; status: terminated.
02
Drugs
voruciclib
03
Conditions
follicular lymphoma (FL)mantle cell lymphoma (MCL)marginal zone lymphoma (MZL)small lymphocytic lymphoma (SLL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03547115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03547115.